For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a devastating condition, the introduction of this treatment and Tafamidis meglumine represents a true change. These groundbreaking therapies protect the transthyretin protein, halting its destructive build-up and alleviating the burden of the illness. Individuals are now se